Kalvista Pharmaceuticals Total Liab Over Time
| KALV Stock | USD 10.10 0.00 0.00% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Kalvista Pharmaceuticals Performance and Kalvista Pharmaceuticals Correlation. Kalvista |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kalvista Pharmaceuticals. If investors know Kalvista will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kalvista Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.57) | Revenue Per Share 0.214 | Quarterly Revenue Growth 0.307 | Return On Assets (0.54) | Return On Equity (0.91) |
The market value of Kalvista Pharmaceuticals is measured differently than its book value, which is the value of Kalvista that is recorded on the company's balance sheet. Investors also form their own opinion of Kalvista Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Kalvista Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kalvista Pharmaceuticals' market value can be influenced by many factors that don't directly affect Kalvista Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kalvista Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kalvista Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kalvista Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Total Liab Analysis
Compare Kalvista Pharmaceuticals and related stocks such as Crinetics Pharmaceuticals, Theseus Pharmaceuticals, and Kura Oncology Total Liab Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CRNX | 18.8 M | 18.8 M | 18.8 M | 18.8 M | 18.8 M | 18.8 M | 18.8 M | 30.6 M | 11.2 M | 13.2 M | 14.5 M | 19.1 M | 35.8 M | 96.2 M | 101.1 M |
| KURA | 31.6 K | 74.8 K | 103.6 K | 133 K | 4.8 M | 5.2 M | 12.9 M | 16 M | 21.4 M | 23.2 M | 36.3 M | 27.4 M | 36 M | 51.7 M | 54.2 M |
| VRDN | 24.2 M | 24.2 M | 24.2 M | 1.6 M | 2.1 M | 2.5 M | 4.6 M | 14 M | 14.8 M | 14.5 M | 11.2 M | 16 M | 40 M | 48.4 M | 50.8 M |
| REPL | 34.3 M | 34.3 M | 34.3 M | 34.3 M | 34.3 M | 34.3 M | 34.3 M | 93.2 M | 16.5 M | 50.4 M | 44.4 M | 50 M | 91.3 M | 113.2 M | 67.8 M |
| NVCT | 10 K | 10 K | 10 K | 10 K | 10 K | 10 K | 10 K | 10 K | 10 K | 10 K | 10 K | 17.7 M | 6.2 M | 7 M | 8.5 M |
| LYRA | 132.4 M | 132.4 M | 132.4 M | 132.4 M | 132.4 M | 132.4 M | 132.4 M | 132.4 M | 132.4 M | 7.6 M | 6.3 M | 20.6 M | 29.2 M | 53.2 M | 33.2 M |
| KRON | 19.9 M | 19.9 M | 19.9 M | 19.9 M | 19.9 M | 19.9 M | 19.9 M | 19.9 M | 19.9 M | 125.9 M | 46.4 M | 46.4 M | 50.4 M | 54.2 M | 45.8 M |
| GOSS | 183 K | 183 K | 183 K | 183 K | 183 K | 183 K | 183 K | 7.3 M | 359.5 M | 74.1 M | 218.7 M | 222.2 M | 260.4 M | 249.1 M | 191.3 M |
| SNDX | 30.8 M | 30.8 M | 30.8 M | 5.2 M | 18.5 M | 23.2 M | 24.9 M | 32.9 M | 30.9 M | 31.9 M | 48.4 M | 41.3 M | 29.8 M | 58.7 M | 34.5 M |
| COGT | 23.2 M | 23.2 M | 23.2 M | 23.2 M | 23.2 M | 23.2 M | 23.2 M | 20.8 M | 25.7 M | 17.7 M | 16.2 M | 17.9 M | 45.1 M | 55.6 M | 30.6 M |
| CGEM | 323 K | 323 K | 323 K | 1 M | 1.2 M | 1.2 M | 578.3 K | 55.3 M | 55.3 M | 140.4 M | 291 M | 11.8 M | 26.1 M | 30.3 M | 55.9 M |
| MRSN | 57.1 M | 57.1 M | 57.1 M | 57.1 M | 57.1 M | 57.1 M | 160.7 M | 60.7 M | 69.7 M | 29.2 M | 45.3 M | 84.4 M | 242.3 M | 189.2 M | 114.7 M |
| IMCR | 139.2 M | 139.2 M | 139.2 M | 139.2 M | 139.2 M | 139.2 M | 139.2 M | 139.2 M | 139.2 M | 170.9 M | 141.8 M | 130.2 M | 156.8 M | 228.2 M | 177.3 M |
| MIRM | 62.3 M | 62.3 M | 62.3 M | 62.3 M | 62.3 M | 62.3 M | 62.3 M | 62.3 M | 62.3 M | 16.4 M | 68.8 M | 174.4 M | 210.9 M | 398 M | 417.8 M |
| LRMR | 13.1 M | 13.1 M | 13.1 M | 13.1 M | 13.1 M | 20 M | 9.9 M | 27.3 M | 28.5 M | 5.9 M | 15 M | 14.3 M | 15.5 M | 14.2 M | 13.1 M |
| CYTK | 82.9 M | 4.6 M | 6.1 M | 28.7 M | 40.9 M | 46.6 M | 75.8 M | 185 M | 185.2 M | 300.8 M | 420.4 M | 597.5 M | 1.1 B | 1.2 B | 1.3 B |
| EWTX | 41.4 M | 41.4 M | 41.4 M | 41.4 M | 41.4 M | 41.4 M | 41.4 M | 41.4 M | 41.4 M | 41.4 M | 164.6 M | 10.8 M | 20.4 M | 21.2 M | 41.3 M |
| DYN | 8.7 B | 3 B | 2 B | 3.1 B | 8.2 B | 8.6 B | 11 B | 9.9 B | 13.1 M | 2.4 M | 11 M | 57.5 M | 54 M | 73.8 M | 70.1 M |
Kalvista Pharmaceuticals and related stocks such as Crinetics Pharmaceuticals, Theseus Pharmaceuticals, and Kura Oncology Total Liab description
The total amount of all liabilities that a company has, including both short-term and long-term liabilities.My Equities
My Current Equities and Potential Positions
| Kalvista Pharmaceuticals | KALV |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 10.1
Additional Tools for Kalvista Stock Analysis
When running Kalvista Pharmaceuticals' price analysis, check to measure Kalvista Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kalvista Pharmaceuticals is operating at the current time. Most of Kalvista Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kalvista Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kalvista Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kalvista Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.